CB
Commit Biologics
Add a description for facebook
BioTech
Built from public sources. Run Commit Biologics? Claim this page with your @commitbio.com email.
Overview
In the news · Nov 18, 2026Commit Biologics: €54M ($60M) Seed, led by Ackermans & van Haaren. The Copenhagen biotech is working on cancer and autoimmune therapies. Raised €54 million Seed. Read the funding digest
About
Makes immunotherapies that work without T cells. For cancer and autoimmune diseases, using complement activation.
Commit Biologics is a biotech company developing complement-powered immune engagers, a new class of immunotherapies for oncology and autoimmune diseases. The company's BiCE platform activates the complement system to eliminate diseased cells, offering an alternative to T cell-based therapies that works independently of T cell function and presence.
Problem & Solution
The problem
Existing T cell-based immunotherapies like CAR-T cells and T cell engagers have limitations: they require sufficient functional T cells in patients, depend on direct contact between T cells and diseased cells, and carry risks of cytokine release and immune-related side effects. Additionally, many tissues and tumors are poorly infiltrated by T cells.
The solution
Commit Biologics developed BiCE (Bispecific Complement Engagers), a platform that recruits the complement protein C1q directly to diseased cells, triggering potent complement activation and immune-mediated cell killing independent of T cell function. The BiCE platform maintains the safety, stability and manufacturability of conventional antibodies while enabling a new mechanism for targeted cell elimination.
More from the same digest
Isomorphic LabsIsomorphic Labs is building a future where frontier AI can help to unlock deeper scientific insights, faster breakthroughs, and life-changing medicines.- Genesis AI
- Model ML
Gathered from the news article and commitbio.com. Not edited by Commit Biologics yet.
Run Commit Biologics? Make this page yours.
Claim it with your @commitbio.com email, fix what we got wrong, and share one clean link with investors and customers.
startupcorners